Drug Trial Radar · NCT05069350
Bupivacaine vs Oxybuprocaine Topical Anesthesia in IVI
Last checked: Nov 20, 2026Latest source record: Sep 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Sep 1, 2021
Primary completion
Aug 1, 2022
Study completion Aug 1, 2022
Sponsor
- Lead sponsor
- Research Institute of Ophthalmology, EgyptAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2021
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
comparing two local anaesthetic agents, Bupivacaine 0.5% versus Oxybuprocaine used topically to provide surface anaesthesia before IVI procedures.
Conditions
- Pain, Acute
Interventions
bupivacaine 0.5% and oxubuprocaineDrug
using each drug as surface anesthesia before intravitreal injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- verbal pain numerical scalingTime frame: 10 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Institute of Ophthamology
Giza, Haram, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.